Ocular Therapeutix Inc (OCUL) reported a Q3 2025 loss of $0.38 per share, falling short of the Wall Street consensus estimate of $-0.37. Revenue remained at $0.0 billion, aligning with analyst expectations but lacking growth.
The company will host an earnings conference call to discuss these results and provide additional context on its business performance.
This update provides insight into Ocular Therapeutix's operational challenges amid a competitive landscape. The company, headquartered in Bedford, Massachusetts, focuses on developing therapies for eye diseases and conditions. Its investigational product candidate, AXPAXLI, targets retinal disease using the ELUTYX bioresorbable hydrogel technology. The pipeline also includes DEXTENZA, a corticosteroid for post-surgical ocular inflammation, and PAXTRAVA, an intracameral hydrogel for treating open-angle glaucoma.
Ocular Therapeutix has a market capitalization of $2.26 billion and a trailing twelve-month EPS of -1.28. Upcoming earnings reports are scheduled for May 3, 2026, and August 2, 2026, with estimated EPS of -0.3582 and -0.3727, respectively.